永利股份 reported revenue of ¥1.30B for the period ended 2026-06-30, +13.6% year on year. Net income was ¥0.12B, a 9.0% net margin on a 32.0% gross margin. The largest revenue line is 轻型输送带 at 50% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.30B | +13.6% |
| Gross profit | ¥0.41B | — |
| Operating income | ¥0.13B | — |
| Net income | ¥0.12B | -3.0% |
| Gross margin | 32.0% | Net margin 9.0% |
| Revenue Q/Q | +21.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 轻型输送带 | ¥0.65B | 50.5% |
| 精密模塑 | ¥0.64B | 49.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.88B | 68.0% |
| R&D | ¥0.04B | 3.2% |
| SG&A | ¥0.22B | 16.9% |
| Tax & other | ¥0.01B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥4.25B |
| Total liabilities | ¥0.97B |
| Shareholders' equity | ¥3.28B |
| Equity / assets | 77.1% |
| Operating cash flow | ¥0.07B |
| Capital expenditure | ¥0.07B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | 57% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
银信科技 ・ 洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies